Pharmafile Logo

The science is shifting in oncology: Are you ready to evolve with it?

August 19, 2025 | Inizio, oncology 

- PMLiVE

Patty Zipfel, PhD, SVP, Scientific Strategy, Inizio Evoke.

This year’s ASCO® meeting spotlighted a bold shift in oncology: the possibility of curing metastatic disease. A new trial design in metastatic breast cancer introduced a ground-breaking endpoint – patients progression-free at four years – challenging long-held assumptions.

Key themes included the rise of CAR-T therapies in solid tumors, the dominance of ADCs, and the expanding role of biomarkers in driving precision medicine. Emerging tools like AI-powered biomarker detection and ctDNA for real-time monitoring are reshaping how sequencing, resistance, and adaptive treatments are approached.

Beyond the science, ASCO® 2025 underscored a new strategic imperative: it’s no longer enough to track progress – we must rethink how we plan, communicate, and act on these advances.

Read Patty’s full article here. Watch Inizio’s webinar recap Beyond the booth: Big ideas, smart spaces & strategic insights from ASCO® 2025 on demand for the full breakdown.

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Getting to grips with Russia’s healthcare market

As a non-Russian, trying to understand the complexities of the multiple overlapping levels of Russia’s healthcare system can be baffling at times. Information is often inaccessible or data simply doesn't...

Pegasus shortlisted for ‘PM Society Digital Media Awards 2014’

Brighton-based independent healthcare specialist continues to showcase its digital expertise with shortlist nomination

Exploring MINT: Part 3 – Nigeria

In the third of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Nigeria.

Exploring MINT: Part 2 – Indonesia

In the second of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Indonesia, with...

Pegasus Wins ‘Consultancy of the Year’ at Communiqué Awards 2014

Pegasus, the UK’s leading independent health communications consultancy, picked up the much coveted ‘Consultancy of the Year’ award at last week’s Communiqué Awards 2014, fighting off stiff competition from the...

Free Thinking: Leveraging the ASEAN Market

If you can only research one ASEAN market, which one do you choose?Our Free Thinking paper investigates the opportunities for pharma in ASEAN and outlines the factors you need to...

Free Thinking: Biosimilars: Friend or foe to healthcare?

Our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.

The Next Billion Patients

Marc Yates, Director of Emerging Markets at pharma market research specialist Research Partnership, shares insights from his experience of working in BRIC and beyond.

Huge Untapped Growth Potential of ASEAN

Marc Yates, Director of Emerging Markets at pharma market research specialist Research Partnership, shares insights from his experience of working in BRIC and beyond.

The power of observation in gathering patient insights

Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding.